E
Erin M. Scherer
Researcher at Emory University
Publications - 7
Citations - 1318
Erin M. Scherer is an academic researcher from Emory University. The author has contributed to research in topics: Antigen & Antibody. The author has an hindex of 5, co-authored 7 publications receiving 765 citations.
Papers
More filters
Journal ArticleDOI
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
Lakshmanane Premkumar,Bruno Segovia-Chumbez,Ramesh Jadi,David R. Martinez,Rajendra Raut,Alena J. Markmann,Caleb Cornaby,Luther A. Bartelt,Susan R. Weiss,Yara A. Park,Caitlin E. Edwards,Eric T. Weimer,Erin M. Scherer,Nadine Rouphael,Srilatha Edupuganti,Daniela Weiskopf,Longping V. Tse,Yixuan J. Hou,David M. Margolis,Alessandro Sette,Alessandro Sette,Matthew H. Collins,John L. Schmitz,Ralph S. Baric,Aravinda M. de Silva +24 more
TL;DR: Results, which reveal the early kinetics of Sars-CoV-2 antibody responses, support using the RBD antigen in serological diagnostic assays and RBD-specific antibody levels as a correlate of SARS-Co V-2 neutralizing antibodies in people.
Journal ArticleDOI
Rapid generation of neutralizing antibody responses in COVID-19 patients
Mehul S. Suthar,Mehul S. Suthar,Matthew G. Zimmerman,Matthew G. Zimmerman,Robert C. Kauffman,Grace Mantus,Susanne L. Linderman,William H. Hudson,Abigail Vanderheiden,Abigail Vanderheiden,Lindsay E. Nyhoff,Carl W. Davis,Oluwaseyi Adekunle,Maurizio Affer,Melanie A. Sherman,Stacian Reynolds,Hans Verkerke,David Alter,Jeannette Guarner,Janetta Bryksin,Michael Horwath,Connie M. Arthur,Natia Saakadze,Geoffrey H. Smith,Srilatha Edupuganti,Erin M. Scherer,Kieffer Hellmeister,Andrew Cheng,Juliet A. Morales,Andrew S. Neish,Sean R. Stowell,Filipp Frank,Eric A. Ortlund,Evan J. Anderson,Vineet D. Menachery,Nadine Rouphael,Aneesh K. Mehta,David S. Stephens,Rafi Ahmed,John D. Roback,Jens Wrammert +40 more
TL;DR: A cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients, which has implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.
Posted ContentDOI
Rapid generation of neutralizing antibody responses in COVID-19 patients.
Mehul S. Suthar,Matthew G. Zimmerman,Robert C. Kauffman,Grace Mantus,Susanne L. Linderman,Abigail Vanderheiden,Lindsay E. Nyhoff,Carl W. Davis,Seyi Adekunle,Maurizio Affer,Melanie A. Sherman,Stacian Reynolds,Hans Verkerke,David Alter,Jeannette Guarner,Janetta Bryksin,Michael Horwath,Connie M. Arthur,Natia Saakadze,Geoffrey H. Smith,Srilatha Edupuganti,Erin M. Scherer,Kieffer Hellmeister,Andrew Cheng,Juliet A. Morales,Andrew S. Neish,Sean R. Stowell,Filipp Frank,Eric A. Ortlund,Evan J. Anderson,Vineet D. Menachery,Nadine Rouphael,Aneesh Metha,David S. Stephens,Rafi Ahmed,John D. Roback,Jens Wrammert +36 more
TL;DR: The dynamics of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in 44 COVID-19 patients revealed the magnitude of RBD-specific IgG binding titers correlated strongly with viral neutralization.
Posted ContentDOI
The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies
Lakshmanane Premkumar,Bruno Segovia-Chumbez,Ramesh Jadi,David R. Martinez,Rajendra Raut,Alena J. Markmann,Caleb Cornaby,Luther A. Bartelt,Susan R. Weiss,Yara A. Park,Caitlin E. Edwards,Eric T. Weimer,Erin M. Scherer,Nadine Roupael,Sri Edupuganti,Daniela Weiskopf,Longping V. Tse,Yixuan J. Hou,David J. Margolis,Alessandro Sette,Alessandro Sette,Matthew H. Collins,John L. Schmitz,Ralph S. Baric,Aravinda M. de Silva +24 more
TL;DR: The results, which reveal the early kinetics of SARS-CoV-2 antibody responses, strongly support the use of RBD-based antibody assays for population-level surveillance and as a correlate of neutralizing antibody levels in people who have recovered from Sars-Cov-2 infections.
Journal ArticleDOI
Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies.
Rachael E. Whaley,Sarah Ameny,Tanvi Arkatkar,Aaron Seese,Abigail Wall,Iram F. Khan,Joseph J. Carter,Erin M. Scherer,David J. Rawlings,Denise A. Galloway,M. Juliana McElrath,Kristen W. Cohen,Andrew T. McGuire,Andrew T. McGuire +13 more
TL;DR: It is shown that this approach can be used to isolate B cells that secrete antibodies that neutralize human papilloma virus (HPV) from participants of an HPV vaccine study.